Rheumatoid Arthritis Ra Epidemiology Forecast

DelveInsight’s ‘Rheumatoid Arthritis (RA) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted RA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017–2030


Rheumatoid Arthritis (RA) Understanding

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.


Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of patient’s symptoms, results of doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.

More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.


Epidemiology Perspective by DelveInsight

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

In 2017, the total diagnosed prevalent cases of RA in the 7MM were 3,825,649, which will probably rise during the study period, i.e., 2017–2030.

In the 7MM, the total gender-specific prevalent cases of RA were 1,007,646 for males and 2,818,003 for females in the year 2017.

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA,

Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.


Country Wise- RA Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.

  • The United States, in 2017, accounted for 1,333,290 RA prevalent cases, which are expected to grow during the study period, i.e., 2017–2030.
  • In the year 2017, the total prevalent cases of RA in EU5 were 1,956,920, which are expected to grow during the study period, i.e., 2017–2030.
  • In the year 2017, the total prevalent cases of RA in Japan were 1,066,584, which are expected to grow during the study period, i.e., 2017–2030.


Scope of the Report

  • The RA report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The RA Report and Model provide an overview of the risk factors and global trends of RA in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of RA in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of RA.
  • The report provides the segmentation of the RA epidemiology by prevalent cases in the 7MM.
  • The report provides the segmentation of the RA epidemiology by diagnosed cases in the 7MM.
  • The report provides the segmentation of the RA epidemiology by gender-specific cases in the 7MM.
  • The report provides the segmentation of the RA epidemiology of diagnosed cases by age distribution in the 7MM.
  • The report provides the segmentation of the RA epidemiology by severity-specific cases in the 7MM.
  • The report provides the segmentation of the RA epidemiology by patient on targeted therapies in the 7MM.
  • The report provides the segmentation of the RA epidemiology by line-wise treated cases of RA in the 7MM.


Report Highlights

  • 11-Year Forecast of RA epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of RA
  • Total Diagnosed Cases of RA
  • Gender-Specific Cases of RA
  • Age distribution Cases of RA
  • Severity-Specific Cases of RA
  • Patient on targeted therapies of RA
  • Line-wise treated cases of RA


KOL-Views

We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to RA?
  • What are the key findings pertaining to the RA epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
  • What would be the total number of patients of RA across the 7MM during the study period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of RA?


Reasons to buy

The RA Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global RA market
  • Quantify patient populations in the global RA market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for RA therapeutics in each of the markets covered
  • Understand the magnitude of RA population by its severity
  • The RA epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The RA Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Rheumatoid Arthritis (RA)

3. RA: Disease Background and Overview

3.1. Introduction

3.2. Stages of RA

3.3. Types of RA

3.3.1. Seropositive RA

3.3.2. Seronegative RA

3.4. Signs and Symptoms of RA

3.5. Risk Factors and Causes of RA

3.6. Complications of RA

3.7. Pathogenesis of RA

3.7.1. Disease Initiation

3.7.2. Triggers of Disease

3.7.3. Citrullination

3.7.4. Early and established RA

3.7.5. Propagation of Disease

3.8. Diagnosis of RA

3.9. Screening of RA

3.10. Rationale and Impact for investigations following the diagnosis: NICE 2020

3.11. Evaluations of Disease Activity in RA

3.12. American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 classification criteria for RA

4. Epidemiology and Patient Population

4.1. Epidemiology Key Findings

4.2. Assumptions and Rationale: 7MM

5. Epidemiology Scenario: 7MM

5.1. Total Prevalent Cases of RA in the 7MM

5.2. Total Diagnosed Prevalent Cases of RA in the 7MM

5.3. Gender-specific Prevalent Cases of RA in the 7MM

5.4. Age-specific Prevalent Cases of RA in the 7MM

5.5. Severity-specific Prevalent Cases of RA in the 7MM

5.6. Patients on targeted therapies of RA in the 7MM

5.7. Line-Wise Treated Cases of RA in the 7MM

6. The United States Epidemiology

6.1. Total Prevalent Cases of RA in the United States

6.2. Total Diagnosed Prevalent Cases of RA in the United States

6.3. Gender-specific Prevalent Cases of RA in the United States

6.4. Age-specific Prevalent Cases of RA in the United States

6.5. Severity-specific Prevalent Cases of RA in the United States

6.6. Patients on targeted therapies of RA in the United States

6.7. Line-Wise Treated Cases of RA in the United States

7. EU-5 Epidemiology

7.1. Germany

7.1.1. Total Prevalent Cases of RA in Germany

7.1.2. Total Diagnosed Prevalent Cases of RA in Germany

7.1.3. Gender-specific Prevalent Cases of RA in Germany

7.1.4. Age-specific Prevalent Cases of RA in Germany

7.1.5. Severity-specific Prevalent Cases of RA in Germany

7.1.6. Patients on targeted therapies of RA in Germany

7.1.7. Line-Wise Treated Cases of RA in Germany

7.2. France

7.2.1. Total Prevalent Cases of RA in France

7.2.2. Total Diagnosed Prevalent Cases of RA in France

7.2.3. Gender-specific Prevalent Cases of RA in France

7.2.4. Age-specific Prevalent Cases of RA in France

7.2.5. Severity-specific Prevalent Cases of RA in France

7.2.6. Patients on targeted therapies of RA in France

7.2.7. Line-Wise Treated Cases of RA in France

7.3. Italy

7.3.1. Total Prevalent Cases of RA in Italy

7.3.2. Total Diagnosed Prevalent Cases of RA in Italy

7.3.3. Gender-specific Prevalent Cases of RA in Italy

7.3.4. Age-specific Prevalent Cases of RA in Italy

7.3.5. Severity-specific Prevalent Cases of RA in Italy

7.3.6. Patients on targeted therapies of RA in Italy

7.3.7. Line-Wise Treated Cases of RA in Italy

7.4. Spain

7.4.1. Total Prevalent Cases of RA in Spain

7.4.2. Total Diagnosed Prevalent Cases of RA in Spain

7.4.3. Gender-specific Prevalent Cases of RA in Spain

7.4.4. Age-specific Prevalent Cases of RA in Spain

7.4.5. Severity-specific Prevalent Cases of RA in Spain

7.4.6. Patients on targeted therapies of RA in Spain

7.4.7. Line-Wise Treated Cases of RA in Spain

7.5. The United Kingdom

7.5.1. Total Prevalent Cases of RA in the United Kingdom

7.5.2. Total Diagnosed Prevalent Cases of RA in the United Kingdom

7.5.3. Gender-specific Prevalent Cases of RA in the United Kingdom

7.5.4. Age-specific Prevalent Cases of RA in the United Kingdom

7.5.5. Severity-specific Prevalent Cases of RA in the United Kingdom

7.5.6. Patients on targeted therapies of RA in the United Kingdom

7.5.7. Line-Wise Treated Cases of RA in the United Kingdom

8. Japan Epidemiology

8.1. Total Prevalent Cases of RA in Japan

8.2. Total Diagnosed Prevalent Cases of RA in Japan

8.3. Gender-specific Prevalent Cases of RA in Japan

8.4. Age-specific Prevalent Cases of RA in Japan

8.5. Severity-specific Prevalent Cases of RA in Japan

8.6. Patients on targeted therapies of RA in Japan

8.7. Line-Wise Treated Cases of RA in Japan

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Summary of Rheumatoid Arthritis (RA) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total Prevalent Cases of RA in the 7MM (2017–2030)

Table 3: Total Diagnosed Prevalent Cases of RA in the 7MM (2017–2030)

Table 4: Gender-specific Prevalent Cases of RA in the 7MM (2017–2030)

Table 5: Age-specific Prevalent Cases of RA in the 7MM (2017–2030)

Table 6: Severity-specific Prevalent Cases of RA in the 7MM (2017–2030)

Table 7: Total Patients on targeted therapies of RA in the 7MM (2017–2030)

Table 8: Line-Wise Treated Cases of RA in the 7MM (2017–2030)

Table 9: Total Prevalent Cases of RA in the United States (2017–2030)

Table 10: Total Diagnosed Prevalent Cases of RA in the United States (2017–2030)

Table 11: Gender-specific Prevalent Cases of RA in the United States (2017–2030)

Table 12: Age-specific Prevalent Cases of RA in the United States (2017–2030)

Table 13: Severity-specific Prevalent Cases of RA in the United States (2017–2030)

Table 14: Patients on targeted therapies of RA in the United States (2017–2030)

Table 15: Line-Wise Treated Cases of RA in the United States (2017–2030)

Table 16: Total Prevalent Cases of RA in Germany (2017–2030)

Table 17: Total Diagnosed Prevalent Cases of RA in Germany (2017–2030)

Table 18: Gender-specific Prevalent Cases of RA in Germany (2017–2030)

Table 19: Age-specific Prevalent Cases of RA in Germany (2017–2030)

Table 20: Severity-specific Prevalent Cases of RA in Germany (2017–2030)

Table 21: Patients on targeted therapies of RA in Germany (2017–2030)

Table 22: Line-Wise Treated Cases of RA in Germany (2017–2030)

Table 23: Total Prevalent Cases of RA in France (2017–2030)

Table 24: Total Diagnosed Prevalent Cases of RA in France (2017–2030)

Table 25: Gender-specific Prevalent Cases of RA in France (2017–2030)

Table 26: Age-specific Prevalent Cases of RA in France (2017–2030)

Table 27: Severity-specific Prevalent Cases of RA in France (2017–2030)

Table 28: Patients on targeted therapies of RA in France (2017–2030)

Table 29: Line-Wise Treated Cases of RA in France (2017–2030)

Table 30: Total Prevalent Cases of RA in Italy (2017–2030)

Table 31: Total Diagnosed Prevalent Cases of RA in Italy (2017–2030)

Table 32: Gender-specific Prevalent Cases of RA in Italy (2017–2030)

Table 33: Age-specific Prevalent Cases of RA in Italy (2017–2030)

Table 34: Severity-specific Prevalent Cases of RA in Italy (2017–2030)

Table 35: Patients on targeted therapies of RA in Italy (2017–2030)

Table 36: Line-Wise Treated Cases of RA in Italy (2017–2030)

Table 37: Total Prevalent Cases of RA in Spain (2017–2030)

Table 38: Total Diagnosed Prevalent Cases of RA in Spain (2017–2030)

Table 39: Gender-specific Prevalent Cases of RA in Spain (2017–2030)

Table 40: Age-specific Prevalent Cases of RA in Spain (2017–2030)

Table 41: Severity-specific Prevalent Cases of RA in Spain (2017–2030)

Table 42: Patients on targeted therapies of RA in Spain (2017–2030)

Table 43: Line-Wise Treated Cases of RA in Spain (2017–2030)

Table 44: Total Prevalent Cases of RA in the United Kingdom (2017–2030)

Table 45: Total Diagnosed Prevalent Cases of RA in the United Kingdom (2017–2030)

Table 46: Gender-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Table 47: Age-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Table 48: Severity-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Table 49: Patients on targeted therapies of RA in the United Kingdom (2017–2030)

Table 50: Line-Wise Treated Cases of RA in the United Kingdom (2017–2030)

Table 51: Total Prevalent Cases of RA in Japan (2017–2030)

Table 52: Total Diagnosed Prevalent Cases of RA in Japan (2017–2030)

Table 53: Gender-specific Prevalent Cases of RA in Japan (2017–2030)

Table 54: Age-specific Prevalent Cases of RA in Japan (2017–2030)

Table 55: Severity-specific Prevalent Cases of RA in Japan (2017–2030)

Table 56: Patients on targeted therapies of RA in Japan (2017–2030)

Table 57: Line-Wise Treated Cases of RA in Japan (2017–2030)

List of Figures

Figure 1: RA SWOT Analysis

Figure 2: Rheumatoid Arthritis (RA) Distressed Area

Figure 3: Stages of Rheumatoid Arthritis

Figure 4: Bone joint differentiation of normal and RA

Figure 5: Development and progression of RA

Figure 6: Types of Rheumatoid Arthritis

Figure 7: Sign and Symptoms of RA

Figure 8: Boggy swelling in proximal interphalangeal and metacarpophalangeal joints (more prominent on the patient’s right hand) in a patient with new-onset RA

Figure 9: Factors contributing to RA development

Figure 10: Associations and links for RA

Figure 11: Initiation and Progression of RA

Figure 12: Clinical manifestations of RA

Figure 13: Antinuclear Antibody Test

Figure 14: Clinical Diagnosis of RA

Figure 15: Diagnostic criteria for RA

Figure 16: Screening for Rheumatoid Arthritis

Figure 17: Total Prevalent Cases of RA in the 7MM (2017–2030)

Figure 18: Total Diagnosed Prevalent Cases of RA in the 7MM (2017–2030)

Figure 19: Gender-specific Prevalent Cases of RA in the 7MM (2017–2030)

Figure 20: Age-specific Prevalent Cases of RA in the 7MM (2017–2030)

Figure 21: Severity-specific Prevalent Cases of RA in the 7MM (2017–2030)

Figure 22: Patients on targeted therapies of RA in the 7MM (2017–2030)

Figure 23: Line-Wise Treated Cases of RA in the 7MM (2017–2030)

Figure 24: Total Prevalent Cases of RA in the United States (2017–2030)

Figure 25: Total Diagnosed Prevalent Cases of RA in the United States (2017–2030)

Figure 26: Gender-specific Prevalent Cases of RA in the United States (2017–2030)

Figure 27: Age-specific Prevalent Cases of RA in the United States (2017–2030)

Figure 28: Severity-specific Prevalent Cases of RA in the United States (2017–2030)

Figure 29: Patients on targeted therapies of RA in the United States (2017–2030)

Figure 30: Line-Wise Treated Cases of RA in the United States (2017–2030)

Figure 31: Total Prevalent Cases of RA in Germany (2017–2030)

Figure 32: Diagnosed Prevalent Cases of RA in Germany (2017–2030)

Figure 33: Gender-specific Prevalent Cases of RA in Germany (2017–2030)

Figure 34: Age-specific Prevalent Cases of RA in Germany (2017–2030)

Figure 35: Severity-specific Prevalent Cases of RA in Germany (2017–2030)

Figure 36: Patients on targeted therapies of RA in Germany (2017–2030)

Figure 37: Line-Wise Treated Cases of RA in Germany (2017–2030)

Figure 38: Total Prevalent Cases of RA in France (2017–2030)

Figure 39: Diagnosed Prevalent Cases of RA in France (2017–2030)

Figure 40: Gender-specific Prevalent Cases of RA in France (2017–2030)

Figure 41: Age-specific Prevalent Cases of RA in France (2017–2030)

Figure 42: Severity-specific Prevalent Cases of RA in France (2017–2030)

Figure 43: Patients on targeted therapies of RA in France (2017–2030)

Figure 44: Line-Wise Treated Cases of RA in France (2017–2030)

Figure 45: Total Prevalent Cases of RA in Italy (2017–2030)

Figure 46: Total Diagnosed Prevalent Cases of RA in Italy (2017–2030)

Figure 47: Gender-specific Prevalent Cases of RA in Italy (2017–2030)

Figure 48: Age-specific Prevalent Cases of RA in Italy (2017–2030)

Figure 49: Severity-specific Prevalent Cases of RA in Italy (2017–2030)

Figure 50: Patients on targeted therapies of RA in Italy (2017–2030)

Figure 51: Line-Wise Treated Cases of RA in Italy (2017–2030)

Figure 52: Total Prevalent Cases of RA in Spain (2017–2030)

Figure 53: Total Diagnosed Prevalent Cases of RA in Spain (2017–2030)

Figure 54: Gender-specific Prevalent Cases of RA in Spain (2017–2030)

Figure 55: Age-specific Prevalent Cases of RA in Spain (2017–2030)

Figure 56: Severity-specific Prevalent Cases of RA in Spain (2017–2030)

Figure 57: Patients on targeted therapies of RA in Spain (2017–2030)

Figure 58: Line-Wise Treated Cases of RA in Spain (2017–2030)

Figure 59: Total Prevalent Cases of RA in the United Kingdom (2017–2030)

Figure 60: Total Diagnosed Prevalent Cases of RA in the United Kingdom (2017–2030)

Figure 61: Gender-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Figure 62: Age-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Figure 63: Severity-specific Prevalent Cases of RA in the United Kingdom (2017–2030)

Figure 64: Patients on targeted therapies of RA in the United Kingdom (2017–2030)

Figure 65: Line-Wise Treated Cases of RA in the United Kingdom (2017–2030)

Figure 66: Total Prevalent Cases of RA in Japan (2017–2030)

Figure 67: Total Diagnosed Prevalent Cases of RA in Japan (2017–2030)

Figure 68: Gender-specific Prevalent Cases of RA in Japan (2017–2030)

Figure 69: Age-specific Prevalent Cases of RA in Japan (2017–2030)

Figure 70: Severity-specific Prevalent Cases of RA in Japan (2017–2030)

Figure 71: Patients on targeted therapies of RA in Japan (2017–2030)

Figure 72: Line-Wise Treated Cases of RA in Japan (2017–2030)

  • Tags:
  • Rheumatoid Arthritis (RA) Epidemiol...
  • Rheumatoid Arthritis (RA)
  • Rheumatoid Arthritis (RA) Pipeline
  • Rheumatoid Arthritis (RA) Companie...
  • Rheumatoid Arthritis (RA) prevalen...
  • Rheumatoid Arthritis (RA) incident...
  • Rheumatoid Arthritis (RA) patients...
  • Rheumatoid Arthritis (RA) treatmen...

Forward to Friend

Need A Quote